RT期刊文章SR电子早期MRI的T1预测值措施长期复发缓和多发性硬化患者的疾病活动接受干扰素β-1a SC tiw或干扰素β-1a IM qw:事后分析证据的神经学研究(P6.189)摩根富林明乔神经病学FD Lippincott Williams &威尔金斯SP P6.189 VO 86是16补充A1 Patricia Coyle A1马克弗里德曼A1费尔南多Dangond A1 Juanzhi方A1安东尼红年2016 UL //www.ez-admanager.com/content/86/16_Supple首页ment/P6.189.abstract AB目的:检查早期MRI不同干扰素beta-1a (IFNβ-1a)治疗和基本病变的关系,后续没有证据表明疾病活动(NEDA)状态。背景:在证据,名RRMS患者被随机分配到干扰素β-1a 44µg皮下注射(SC) 3 x /周(n = 339)或干扰素β-1a 30µg肌内(IM) 1 x /周(n = 338)。方法:事后分析评估是否基线(周[W] 0)病变预测NEDA到W48(没有复发,没有残疾进展(≥1点增加eds分数持续12周),并没有主动T2病灶W48 [7 MRI扫描])和W72(残疾没有复发,没有发展,没有活跃的T2损伤到W72[8核磁共振扫描])。结果:干扰素β-1a SC与更少的意思是Gd +和活跃的T2病灶/耐心/扫描W8和W12,分别与干扰素β-1a IM (Gd + 0.79 vs 1.34, p = 0.002;T2 0.42 vs 0.55, p = 0.008)。更多的干扰素β-1a SC患者实现NEDA W48 (33.2 vs 18.9 [percnt] [percnt], p < 0.001)和W72 (26.4 vs 11.1 [percnt] [percnt], p < 0.001)和干扰素β-1a IM。基线Gd +病变组之间没有显著差异;存在(vs)预测NEDA状态到W72干扰素β-1a IM (2.8 vs 19.4 [percnt] [percnt], p = 0.022),但不是干扰素β-1a SC (16.9 vs 36.3 [percnt] [percnt], p = 0.187)。更多的患者和没有基线Gd +病变取得NEDA到W48 (p≤0.017)和W72 (p≤0.003)与干扰素β-1a SC与干扰素β-1a IM。结论:干扰素β-1a SC证明早期MRI福利和与更多的病人(有或没有基线Gd +病变)实现NEDA,而干扰素β-1a IM。 For IFN β-1a IM, baseline Gd+ lesions were associated with reduced likelihood of having NEDA. Study supported by: EMD Serono, Inc., Rockland, MA, USA (a business of Merck KGaA, Darmstadt, Germany); Pfizer Inc, New York, NY, USA.Disclosure: Dr. Coyle has received research support from Actelion, Biogen, Genentech/Roche, Novartis, and Opexa. Dr. Freedman has received research support from Bayer Healthcare and Genzyme. Dr. Dangond has received personal compensation for activities with EMD Serono, Inc. as an employee. Dr. Fang has received personal compensation for activities with EMD Serono, Inc., Rockland, MA, USA, a subsidiary of Merck KGaA, Darmstadt, Germany. as an employee. Dr. Reder has received personal compensation for activities with Acorda, Bayer, Biogen, EMD Serono, Inc., Genentech, Genzyme, Novartis, Pfizer, Questcor/Malinkrodt, Sanofi, and Teva Pharmaceuticals.Thursday, April 21 2016, 8:30 am-5:30 pm